I think their CORE-NK platform will be their most successful program especially once they integrate the CDH-17 and CLTX biomarkers. It will be allogeneic and can produce the same efficacy rates as CAR-T programs. However, it is still a mystery whether they will work in solid tumours. Crossing into the tumour microenvironment will always be an issue and dealing with tumor evasion due to the variety of biomarkers may affect durability and metastases so we'll see.
They are targetting hematological tumours so you may see the same efficacy rates that we've seen from Nkarta and Fate therapeutics' CAR-NK programs.
valuation thoughts, page-350
-
- There are more pages in this discussion • 31 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add CHM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
2.0¢ |
Change
0.002(11.1%) |
Mkt cap ! $17.25M | |||
| Open | High | Low | Value | Volume |
| 1.9¢ | 2.0¢ | 1.9¢ | $26.18K | 1.372M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 7 | 736556 | 1.8¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 2.0¢ | 1462067 | 5 |
View Market Depth
| Last trade - 16.10pm 28/06/2024 (20 minute delay) ? |
| CHM (ASX) Chart |